Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study (751)
Visual Quality Following Aspheric and Monovision Lens Implantation - a Comparative Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Sir Charles Gairdner Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Senile cataract
- Patient identified as a candidate for cataract surgery and IOL implantation
- Willing to sign informed consent document approved by the Ethical Committee
- Willing to complete all required tests and exams per this protocol
Exclusion Criteria:
- Amblyopia
- History or evidence of any ocular disease that may affect visual acuity
- Previous ocular surgery, including refraction surgery
- Ocular anomalies (e.g. microphthalmos, kerataconous)
- Subjects with greater than 1.0 D of corneal astigmatism
- Subjects who experience intraoperative complications that could affect postoperative IOL centration or tilt
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: FACTORIAL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Both Eyes
Model 751 IOL implanted in both eyes.
|
Aspheric IOL for correction of aphakia
Other Names:
|
|
EXPERIMENTAL: Single eye
Model 751 IOL in one eye
|
Model 751 in one eye, standard IOL in other eye
Other Names:
|
|
ACTIVE_COMPARATOR: Control
Aphakia treatment by negatively aspheric IOL implant, Hoya iSert model 251 or equivalent
|
Negatively aspheric IOL in both eyes
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Uncorrected Visual Acuity (UCVA) (ETDRS)for distance, intermediate and near
Time Frame: Up to 3 months
|
Up to 3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Graham Barrett, MD, Sir Charles Gairdner Hospital, Nedlans WA
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- DOF-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.